 Phenylurea Compounds
"Phenylurea Compounds" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that include the amino-N-phenylamide structure.
| Descriptor ID |
D010671
|
| MeSH Number(s) |
D02.455.426.559.389.703 D02.948.681
|
| Concept/Terms |
Phenylurea Compounds- Phenylurea Compounds
- Compounds, Phenylurea
- Phenylurea Derivatives
- Derivatives, Phenylurea
- Phenylcarbamides
|
Below are MeSH descriptors whose meaning is more general than "Phenylurea Compounds".
Below are MeSH descriptors whose meaning is more specific than "Phenylurea Compounds".
This graph shows the total number of publications written about "Phenylurea Compounds" by people in this website by year, and whether "Phenylurea Compounds" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1992 | 1 | 0 | 1 | | 1997 | 1 | 0 | 1 | | 2000 | 1 | 0 | 1 | | 2002 | 1 | 0 | 1 | | 2005 | 0 | 1 | 1 | | 2006 | 1 | 1 | 2 | | 2007 | 1 | 1 | 2 | | 2008 | 0 | 1 | 1 | | 2009 | 0 | 2 | 2 | | 2010 | 0 | 2 | 2 | | 2011 | 0 | 2 | 2 | | 2012 | 1 | 3 | 4 | | 2013 | 3 | 1 | 4 | | 2014 | 2 | 2 | 4 | | 2015 | 4 | 1 | 5 | | 2016 | 3 | 3 | 6 | | 2017 | 2 | 0 | 2 | | 2018 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Phenylurea Compounds" by people in Profiles.
-
Cortes JE, Heidel FH, Hellmann A, Fiedler W, Smith BD, Robak T, Montesinos P, Pollyea DA, DesJardins P, Ottmann O, Ma WW, Shaik MN, Laird AD, Zeremski M, O'Connell A, Chan G, Heuser M. Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. Leukemia. 2019 02; 33(2):379-389.
-
Gregory MA, Nemkov T, Reisz JA, Zaberezhnyy V, Hansen KC, D'Alessandro A, DeGregori J. Glutaminase inhibition improves FLT3 inhibitor therapy for acute myeloid leukemia. Exp Hematol. 2018 02; 58:52-58.
-
Zhang C, Liu Z, Bunker E, Ramirez A, Lee S, Peng Y, Tan AC, Eckhardt SG, Chapnick DA, Liu X. Sorafenib targets the mitochondrial electron transport chain complexes and ATP synthase to activate the PINK1-Parkin pathway and modulate cellular drug response. J Biol Chem. 2017 09 08; 292(36):15105-15120.
-
Nogova L, Sequist LV, Perez Garcia JM, Andre F, Delord JP, Hidalgo M, Schellens JH, Cassier PA, Camidge DR, Schuler M, Vaishampayan U, Burris H, Tian GG, Campone M, Wainberg ZA, Lim WT, LoRusso P, Shapiro GI, Parker K, Chen X, Choudhury S, Ringeisen F, Graus-Porta D, Porter D, Isaacs R, Buettner R, Wolf J. Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study. J Clin Oncol. 2017 Jan 10; 35(2):157-165.
-
Bourlon MT, Gao D, Trigero S, Clemons JE, Breaker K, Lam ET, Flaig TW. Clinical significance of sunitinib-associated macrocytosis in metastatic renal cell carcinoma. Cancer Med. 2016 12; 5(12):3386-3393.
-
Gregory MA, D'Alessandro A, Alvarez-Calderon F, Kim J, Nemkov T, Adane B, Rozhok AI, Kumar A, Kumar V, Pollyea DA, Wempe MF, Jordan CT, Serkova NJ, Tan AC, Hansen KC, DeGregori J. ATM/G6PD-driven redox metabolism promotes FLT3 inhibitor resistance in acute myeloid leukemia. Proc Natl Acad Sci U S A. 2016 10 25; 113(43):E6669-E6678.
-
Tabakoff B, Ren W, Vanderlinden L, Snell LD, Matheson CJ, Wang ZJ, Levinson R, Smothers CT, Woodward JJ, Honse Y, Lovinger D, Rush AM, Sather WA, Gustafson DL, Hoffman PL. A novel substituted aminoquinoline selectively targets voltage-sensitive sodium channel isoforms and NMDA receptor subtypes and alleviates chronic inflammatory and neuropathic pain. Eur J Pharmacol. 2016 Aug 05; 784:1-14.
-
Heasley LR, McMurray MA. Small molecule perturbations of septins. Methods Cell Biol. 2016; 136:311-9.
-
Cooper TM, Cassar J, Eckroth E, Malvar J, Sposto R, Gaynon P, Chang BH, Gore L, August K, Pollard JA, DuBois SG, Silverman LB, Oesterheld J, Gammon G, Magoon D, Annesley C, Brown PA. A Phase I Study of Quizartinib Combined with Chemotherapy in Relapsed Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study. Clin Cancer Res. 2016 Aug 15; 22(16):4014-22.
-
Dahl NA, Michaels ST, McMasters RL, Chandra S, O'Brien MM. Azacitidine and Sorafenib Therapy in a Pediatric Patient With Refractory Acute Myeloid Leukemia With Monosomy 7 and Somatic PTPN11 Mutation. Pediatr Blood Cancer. 2016 Mar; 63(3):551-3.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|